The company believes its two-shot regimen is 90 percent effective at preventing infection from Covid, based on clinical trial data.
It is a 'protein based' vaccine that introduces a person's immune system to inactive virus cells - similar to the flu shot and many other common vaccines - in order to mount a response.
While a majority of Americans have already received a Covid vaccine, the jab's authorization would add to the available options for boosters in America.
Novavax plans to submit data for its Covid vaccine to the FDA by the end of the year, as the company's highly anticipated 'protein based' jab may be available soon
'We'll have a file in the U.S. hopefully before the